Author

Paul A. Frohna 1

1 Celgene, Summit, United States of America

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL RECOMBINANT, HUMANISED, ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY (RPC4046) IN PATIENTS WITH ACTIVE EOSINOPHILIC OESOPHAGITIS: RESULTS OF THE HEROES STUDY

Ikuo Hirano, Margaret H. Collins, Yudith Assouline-Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Michael Grimm, Heather Smith, Cindy-ann Tompkins, Amy Woo, Robert Peach, Paul A. Frohna, Sheila Gujrathi, Richard Aranda, Evan S Dellon

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

EFFECTS OF HIGH- AND LOW-FAT MEALS ON THE PHARMACOKINETICS OF OZANIMOD, A NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR

Jonathan Q. Tran, Jeffrey P Hartung, Cindy-ann Tompkins, Paul A. Frohna

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH OZANIMOD, AND ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: TOUCHSTONE EXTENSION

William Sandborn, Brian G. Feagan, Geert R. D'Haens, Stephen B Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Allan Olson, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda

Item 1 - 4 / 4
1